SCHEMBL3263480

SCHEMBL3263480

Cc1ccc(CNc2ccc(C(=O)N3CCCC(C)C3)cc2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.62
HPGD P15428 5/20 0.62
GAA P10253 2/20 0.62
GRM5 P41594 3/20 0.60
RECQL P46063 1/20 0.55
SMN1; SMN2 Q16637 4/20 0.54
MAPT P10636 3/20 0.54
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
RAB9A P51151 2/20 0.54
NAMPT P43490 1/20 0.54
NPC1 O15118 1/20 0.54
HTT P42858 1/20 0.54
CA12 O43570 1/20 0.53
CA1 P00915 1/20 0.53
CA2 P00918 1/20 0.53
CA7 P43166 1/20 0.53
CA9 Q16790 1/20 0.53
CA14 Q9ULX7 1/20 0.53
LMNA P02545 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3235638 0.90 HSD11B1 (0.62) ALDH1A1HPGDGAAGRM5RECQL
SCHEMBL3237608 0.90 GRM5 (0.75) ALDH1A1HPGDGAAGRM5RECQL
SCHEMBL20394973 0.90 NAMPT (0.61) ALDH1A1HPGDGAAGRM5RECQL
SCHEMBL3263478 0.86 HPGD (0.60) ALDH1A1HPGDGAAGRM5RECQL
SCHEMBL3456176 0.85 RECQL (0.73) ALDH1A1HPGDGRM5RECQLSMN1; SMN2
SCHEMBL3236009 0.83 GRM5 (0.64) ALDH1A1HPGDGAAGRM5SMN1; SMN2
SCHEMBL6684885 0.80 RECQL (0.82) ALDH1A1HPGDGAAGRM5RECQL
SCHEMBL3379922 0.78 GRM5 (0.60) ALDH1A1HPGDGAAGRM5RECQL
SCHEMBL14297352 0.77 KMT2A (0.62) ALDH1A1HPGDGRM5RECQLMEN1
SCHEMBL3235633 0.76 KMT2A (0.61) ALDH1A1HPGDGAAGRM5RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2344456-B1 NOVEL POTASSIUM CHANNEL BLOCKER JAPAN TOBACCO INC (JP) 2018-07-25 EP claimed
US-8258138-B2 Potassium channel blockers XENTION LIMITED (GB) 2012-09-04 US claimed
US-20100087437-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US claimed
WO-2010023445-A1 NOVEL POTASSIUM CHANNEL BLOCKER XENTION LIMITED (GB) 2010-03-04 WO claimed
EP-2344456-B1 NOVEL POTASSIUM CHANNEL BLOCKER JAPAN TOBACCO INC (JP) 2018-07-25 EP disclosed
US-8258138-B2 Potassium channel blockers XENTION LIMITED (GB) 2012-09-04 US disclosed
US-20100087437-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US disclosed
WO-2010023445-A1 NOVEL POTASSIUM CHANNEL BLOCKER XENTION LIMITED (GB) 2010-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087437-A1 Novel Potassium Channel Blockers KCNB1, KCNJ2, KCNJ11 ALDH1A1 1588/4885HPGD 3739/4885GAA 3857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.